Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nanvuranlat (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Biliary cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Beacon-BTC
  • Sponsors J-Pharma

Most Recent Events

  • 23 Jan 2026 Planned initiation date (estimated date of first participant enrollment) changed from 1 Dec 2025 to 1 Jan 2026.
  • 23 Jan 2026 Status changed from not yet recruiting to recruiting.
  • 09 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top